Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for banking industry professionals · Wednesday, August 21, 2019 · 494,167,677 Articles · 3+ Million Readers

Aurora-GT (Endothelial Nitric Oxide-Synthase-Enhanced Endothelial Progenitor Cells) Drug Overview

/EIN News/ -- Dublin, July 16, 2019 (GLOBE NEWSWIRE) -- The "Aurora-GT" report has been added to ResearchAndMarkets.com's offering.

United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells), which is intended to rebuild blood vessels in the lung. Administering this gene therapy involves isolating a PAH patient's autologous endothelial progenitor cells, transfecting the cells with the gene for human endothelial NO-synthase, prior to their ex-vivo expansion, and reintroducing them into the same patient.

Analyst Outlook

United Therapeutics is aiming to diversify its pulmonary hypertension (PH) portfolio with a pipeline gene therapy product, Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells). The company stands out as the only one with a late-phase gene therapy in development. If successful, this therapy could address critical unmet need in the PH market for options beyond symptomatic treatment. The author awaits further developments for Aurora-GT, as Phase II/III clinical trial data are yet to be released.

Key Topics Covered:

OVERVIEW

  • Drug Overview
  • Product Profiles
  • Aurora-GT : Pulmonary hypertension

LIST OF FIGURES
Figure 1: Aurora-GT for pulmonary hypertension - SWOT analysis

LIST OF TABLES
Table 1: Aurora-GT drug profile
Table 2: Aurora-GT Phase II trial in pulmonary hypertension

For more information about this report visit https://www.researchandmarkets.com/r/gcn35j

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Respiratory Drugs
                    

22157.jpg

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release